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The hallmarks of human malignant gliomas are their marked inva-
siveness and vascularity. Glioma tumour cells invade beyond the
main tumour mass at diagnosis (Burger et al, 1983; Kelly et al,
1987) and render these surgically incurable. Since angiogenesis
and tumour invasion have been associated with increased extra-
cellular matrix (ECM) degradation in which the matrix metallo-
proteinase (MMP) family of enzymes plays a critical role, the
involvement of MMPs in glioma biology is coming under
increasing scrutiny.
MMPs are the principal secreted proteinases required for ECM
degradation in a variety of physiological and pathological tissue
remodelling processes, including wound healing, embryo implan-
tation, tumour invasion, metastasis and angiogenesis (Woessner,
1991; Aznavoorian et al, 1993; Mignatti and Rifkin, 1993).
At least 18 MMPs have been described (Pendas et al, 1997; Yong
et al, 1998), which are subdivided into the collagenases,
stromelysins, gelatinases and membrane-type MMPs (MT-MMPs)
(Sato, 1994). Their activities are controlled at the levels of gene
transcription, zymogen activation by proteolysis and inhibition of
active forms by the tissue inhibitors of metalloproteinases
(TIMPs) (Edwards et al, 1996). There is a wealth of evidence
for an association between either deregulated MMPs and aggres-
sive/invasive behaviour in human cancers (Davies et al, 1993;
Bernhard et al, 1994; Heppner et al, 1996). This is particularly
significant for gelatinase-A (MMP-2) and gelatinase-B (MMP-9)
since these are critical factors in basement membrane degradation.
Gelatinase-A and gelatinase-B are controlled through distinct
mechanisms. Progelatinase-A is widely expressed and is activated
by a cell surface mechanism involving MT-1, -2 or -3 MMPs
(Butler et al, 1997; Murphy and Knauper, 1997; Ueno et al, 1997).
In contrast, progelatinase-B is controlled primarily at the level of
gene expression, its transcription being activated by mitogens and
inflammatory mediators (Azzam et al, 1993; Cornelius et al, 1995;
Edwards et al, 1996). Furthermore, it is not activated by MT-
MMPs, but is activated more promiscuously by plasmin,
stromelysin-1 and gelatinase-A (Murphy and Knauper, 1997). The
levels of active, rather than latent, gelatinase-A correlate best with
the invasive cancer phenotype (Azzam et al, 1993; Brown et al,
1993); in breast cancer MT1-MMP is its activator (Ueno et al,
1997).
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Summary Matrix metalloproteinases (MMPs) have been implicated as important factors in gliomas since they may both facilitate invasion into
the surrounding brain and participate in neovascularization. We have tested the hypothesis that deregulated expression of gelatinase-A or B,
or an activator of gelatinase-A, MT1-MMP, may contribute directly to human gliomas by quantifying the expression of these MMPs in 46 brain
tumour specimens and seven control tissues. Quantitative RT-PCR and gelatin zymography showed that gelatinase-A in glioma specimens
was higher than in normal tissue; these were significantly elevated in low grade gliomas and remained elevated in GBMs. Gelatinase-B
transcript and activity levels were also higher than in normal brain and more strongly correlated with tumour grade. We did not see a close
relationship between the levels of expression of MT1-MMP mRNA and amounts of activated gelatinase-A. In situ hybridization localized
gelatinase-A and MT1-MMP transcripts to normal neuronal and glia, malignant glioma cells and blood vessels. In contrast, gelatinase-B
showed a more restricted pattern of expression; it was strongly expressed in blood vessels at proliferating margins, as well as tumour cells in
some cases. These data suggest that gelatinase-A, -B and MT1-MMP are important in the pathophysiology of human gliomas. The primary
role of gelatinase-B may lie in remodelling associated with neovascularization, whereas gelatinase-A and MT1-MMP may be involved in both
glial invasion and angiogenesis.
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University Ave, Toronto Ontario, Canada M5G 2L7Gelatinase-A, -B and MT1-MMP are over-expressed in glioma
cell lines/surgical specimens (Apodaca et al, 1990; Nakano et al,
1993, 1995; Rao et al, 1993, 1996; Nakagawa et al, 1994, 1996;
Rutka et al, 1995; Saxena et al, 1995; Sawaya et al, 1996; Uhm
et al, 1996; Yamamoto et al, 1996; Forsyth et al, 1998).
Immunohistochemistry shows gelatinase-A, -B, and MT1-MMP in
glioma tumour cells (Costello et al, 1994; Nakagawa et al, 1994;
Rao et al, 1996; Sawaya et al, 1996; Yamamoto et al, 1996). The
distribution of gelatinase-A and -B may be different, however, in
the tumour microvasculature. Some found both gelatinase-A and -
B in endothelial cells (Costello et al, 1994; Rao et al, 1996;
Sawaya et al, 1996) but others found only gelatinase-B in the
tumour microvasculature (Nakagawa et al, 1994). This difference
in the spatial distribution suggests the function of these in gliomas
may be quite different. We hypothesize that gelatinase-B may be
more important in neovascularization where it may be used by
capillary endothelial cells to degrade the basement membrane and
allow them to migrate towards the angiogenic stimuli; endothelial
cells are known to produce MMPs and TIMPs in-vitro
(Hanemaaijer et al, 1993; Cornelius et al, 1995; Lewalle et al,
1995; Zucker et al, 1995; Foda et al, 1996).
We compared the expression of gelatinase-A, -B and MT1-
MMP in 47 brain tumour specimens to seven control tissues and
tested the hypothesis that deregulated expression of gelatinase-A
or -B, or the activator of gelatinase-A, MT1-MMP, may contribute
to the aggressiveness of human gliomas. By studying these three
MMPs simultaneously in a large number of the same tumour
samples, we hoped to clarify their respective roles in glioma
biology.
MATERIALS AND METHODS
Tissue collection
Procedures on patients were performed under a general anaesthetic
and tumour specimens placed immediately in liquid nitrogen and
stored at –80°C. The cervical lymph node containing the metas-
tasis of patient no.1 was obtained at autopsy by dissection, snap
frozen in liquid nitrogen and stored at –80°C. This study has the
approval of our institutional ethics board. All patients gave signed,
informed consent for their tissue to be used. The following tissues
were studied: 19 glioblastoma multiforme (GBMs) (including two
from the patients with extraneural metastases), one cervical metas-
tasis from a GBM, five meningiomas (M), seven anaplastic astro-
cytomas (AA), five malignant oligodendrogliomas (MO), eight
low grade gliomas (LGG), one clival chordoma and one spinal
ependymoma; these were compared to seven controls (two normal
brain samples obtained during non-brain tumour surgery and five
from autopsy). All glioma tissue was obtained from regions of
tumour corresponding to actively growing tumour; tumour regions
containing only necrosis or relatively normal brain were not
sampled.
Zymography
This in vitro assay uses gelatin-substrate gel electrophoresis to
measure the levels of metalloproteinase activity in tumour
samples. Frozen tissues were pulverized in liquid nitrogen and
homogenized in buffer (0.5 M Tris-HCl, pH 7.6; 0.2 M NaCl;
10 mM CaCl2; 1% Triton-X100) in an Ultra-Turrax-25 homo-
genizer. Ten Milligrams of total protein from homogenate
supernatants were electrophoresed on 10% denaturing sodium
dodecyl sulphate (SDS) polyacrylamide gels containing 1 mg
ml-1 of gelatin. Gels were washed overnight in washing buffer
(50 mM Tris-HCI; pH 8.0; 5 mM CaCl2; 2.5% Triton-X100) and
then incubated for 24 h at 37°C in the above buffer without Triton-
X100 so that renaturation of enzyme could occur. Gels were
stained with Coomassie blue and de-stained. Gelatinolytic activi-
ties were visualized as clear bands against a blue background. Gels
were analysed by computerized densitometric scanning of the
images using a Hewlett-Packard Scan Jet IIc Scanner, Deskscan II
software and the NIH ‘Image’ Program. The size and intensity of
each band were determined and its area plotted on graphs.
RT-PCR
RNA preparation
Total RNA was extracted from cells by the acid guanidinium isoth-
iocyanate method. The final RNA concentrations were determined
by absorption using a GeneQuant spectrophotometer (Pharmacia).
Reverse transcription reactions
Each 20 ml cDNA synthesis reaction contained 1 mg of total RNA,
1 ´ PCR buffer (10 mM Tris-HCl; pH 9.0; 50 mM KCl; 1.5 mM
magnesium chloride), 1 mM each of deoxynucleotide triphos-
phates (dATP, dGTP, dCTP, and dTTP), 20 units placental
ribonuclease inhibitor (RNAguard, Pharmacia), 200 units of
MuLV-reverse transcriptase (RT) (Bethesda Research
Laboratories) and 100 pmol of random hexamer oligodeoxynu-
cleotides (Pharmacia). Reaction mixtures were preincubated
10 min at 21°C prior to cDNA synthesis. The reverse transcription
reactions were carried out for 50 min at 42°C and were heated to
95°C for 5 min to terminate the reaction. Samples were cooled to
4°C or stored at –20°C until use.
PCR reactions
Multiplex PCRs were performed in 50 ml reaction volumes. Each
reaction contained 2 ml of RT reaction product as template DNA
(corresponding to cDNA synthesized from 100 ng of total RNA), 1
´ PCR buffer, 80 mm of each deoxynucleotide (in addition to the
dNTP left over from the RT reaction, resulting in a final concen-
tration of approximately 180 mM) and 20 pmol each of 5¢ and 3¢
target primers. Two units of Taq DNA polymerase (Gibco-BRL)
were added to each tube during the first denaturation step (‘hot
start’) and equal aliquots (20 pmol) of GAPDH primer sets were
added at the appropriate cycle number by the ‘primer dropping’
method (Wong et al, 1994). Each PCR cycle consisted of a heat-
denaturation step at 94°C for 1 min, a primer-annealing step at
55°C for 30 s, and a polymerization step at 72°C for 1 min. PCR
amplifications were performed in a Temp-Tronic Thermal Cycler
(Barnstead/Thermolyne). Aliquots of PCR reaction products
(approximately 10 ml) equalized to give equivalent signals from
the internal control mRNA (GAPDH) were electrophoresed
through 2% agarose gels containing 0.2 mg of ethidium bromide.
To allow quantification of RT-PCR data, an initial ‘cycle test’ was
performed for each sample and primer set to determine the appro-
priate number of cycles required for detection of amplification
products while remaining in the exponential phase of PCR. For
gelatinase-A, gelatinase-B and MT1-MMP amplifications, the
operative cycle numbers were 29, 33 and 30 respectively. GAPDH
primers were added to the last 23 cycles. Gels were illuminated
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with UV light, photographed using Polaroid film, and analysed by
computerized densitometric scanning as described above. The
intensities of the ethidium bromide fluorescence signals were
determined from the area under the curve for each peak and the
data were plotted on graphs.
The following primers were employed:
Gelatinase-A 5¢-primer=5¢-GCGGATCCAGCGCCCAGAGAGACAC
3¢-primer=3¢-TTAAGCTTCCACTCCGGGCAGGATT
Gelatinase-B 5¢-primer= 5¢-TGGACGATGCCTGCAACGTG
3¢-primer= 5¢-GTCGTGCGTGTCCAAAGGCA
MT1-MMP 5¢-primer= 5¢-GCCCATTGGCCAGTTCTGGCCGG
3¢-primer= 5¢-CCTCGTCCACCTCAATGATGATC
GAPDH 5¢-primer= 5¢-CGGAGTCAACGGATTTGGTCGTAT
3¢-primer= 5¢-AGCCTTCTCCATGGTGGTGAAGAC
The size of the amplification products were 473 bp for gelatinase-
A, 454 bp for gelatinase-B, 548 bp for MT1-MMP and 306 bp for
GAPDH respectively.
In situ hybridization for gelatinase-A, -B and MT1-MMP
mRNA
A 348 bp Bgl-BamHI fragment of human gelatinase-A (sequence
corresponding to 1404–1752) was obtained by RT-PCR from
human Hs68 cell RNA and cloned into pBluescript KS-
(Stratagene). The construction of the 390 bp gelatinase-B probe
has been described previously (Urbanski et al, 1992). The MT1-
MMP probe was a 420 bp region encompassing the pro-domain
and part of the catalytic domain, cloned in pBluescript SK+ based
on the sequence of Sato et al (1994) and generously provided by
Dr Suneel Apte, Cleveland Clinic Foundation, Cleveland, OH,
USA. For gelatinase-A, antisense riboprobe was generated with T3
polymerase from template linearized with XbaI, and sense ribo-
probe was produced with T7 polymerase and BamHI-cut plasmid.
Corresponding probes for gelatinase-B involved: T7 polymerase
and HindIII-cut template (antisense), T3 polymerase and NotI-cut
template (sense). For MT1-MMP, we used T3 polymerase and
SalI-cut template (anti-sense); T7 polymerase and EcoRI-cut
plasmid (sense). Riboprobes were prepared and labelled with
digoxygenin (DIG)-labelled-UTP (Boehringer Mannheim, Laval,
Quebec, Canada) following the manufacturer’s instructions.
Confirmation of sense and antisense riboprobe was confirmed by
Northern blot analysis. Antisense probes but not sense probes,
detected a single band of the appropriate size for all three genes.
In situ hybridization was performed as described previously
(Harvey et al, 1995; Leco et al, 1997). Briefly, 4-mm paraffin-
embedded brain sections were dewaxed in xylene and rehydrated
through a series of graded ethanols. Sections were treated with
proteinase K (20 mg ml-1), acetylated and then prehybridized in
buffer containing 50% formamide, 5 ´ SSPE, 1 ´ Denhardt’s solu-
tion, 20 mM DTT for 6 h at 50°C. Hybridization was done at 60°C
overnight in the same buffer to which 20 ng ml-1 of probe and
8 mg ml-1 of Escherichia coli tRNA were added. After hybridiza-
tion, sections were then washed once in 2 ´ SSC at 37°C, treated
with 20 mg ml-1 RNase A at 37°C, washed once in 2 ´ SSC at
50°C, once in 50% formamide at 50°C, twice in 2 ´ SSC at 50°C
and once in 0.5 ´ SSC at 50°C; all for 30 min each time. Following
blocking, sections were incubated in a 1:1000 dilution of sheep
anti-DIG-alkaline phosphatase conjugated antibody (Boehringer
Mannheim), for 4 h at room temperature. After extensive washing,
NBT/BCIP chromogens were applied to sections and colour was
developed in the dark until the desired intensity was obtained. The
reaction was terminated by placing sections in 20 mM Tris-HCl,
pH 7.5, 10 mM EDTA. Sections were then dipped briefly in water,
counter-stained for 3 min in 0.02% fast green, washed for 1 min in
water and mounted with Advantage aqueous mounting medium
(Accurate Chemical). The slides were photographed on Kodak
Royal Gold 35 mm film using a Zeiss photomicroscope II under
bright-field illumination.
Statistical analysis
The quantitative expression of gelatinase-A and -B in terms of
lysis per mg of protein from the zymograms, or in terms of their
transcript intensity for gelatinase-A, -B and MT1-MMP from
RT-PCR were compared using the Kruskal–Wallis test. These
quantitative expressions were correlated with glial malignancy
(normal low grade versus malignant glioma versus GBM) using
Spearman’s rank correlation coefficient. Data for meningiomas
and other brain tumours were plotted but not analysed statistically.
RESULTS
Detection of gelatinase-A, -B, and MT1-MMP mRNA by
RT-PCR analysis
Gelatinase-A, -B and MT1-MMP mRNA expression was evalu-
ated by RT-PCR and compared with frozen samples of histologi-
cally defined normal brain tissue and brain tumours (Figure 1).
Gelatinase-A, -B and MT1-MMP RNA expression was very low
in the normal samples. PCR amplification of cDNA prepared
from frozen samples defined histologically as low grade glioma
(oligodendroglioma, astrocytoma, oligo-astrocytoma, pilocytic
Control LG MA/MO GBM Meningioma
Gelatinase A
GAPDH
GAPDH
Gelatinase B
MT-MMP1
GAPDH
Figure 1 Representative examples of expression of gelatinase-A, -B and
MT1-MMP mRNA using RT-PCR in human brain tumour and normal brain
tissue. Two control samples have low levels of transcripts of all three genes.
Tumour levels of gelatinase-A and MT1-MMP were higher than in normal
tissues and varied somewhat but did not strongly correlate with tumour
malignancy. Gelatinase-B RNA levels were also variable but were much
higher in GBMs than in low grade gliomas. Higher levels of gelatinase-A and
MT1-MMP than gelatinase-B RNAs were seen in meningiomas.
Abbreviations for all Figures: AA = anaplastic astrocytoma; AO = anaplastic
oligodendroglioma; CLN-1 = cervical lymph node metastasis; ENM =
extraneural metastasis; GBM = glioblastoma multiforme; GBM-1, -2 = first
and second GBM patient with extramural metastases; LGG = low grade
glioma; MO/MA = malignant oligodendroglioma or malignant astrocytoma;
N1-7 = normal tissue; Other = 1 clival chordoma and 1 spinal ependymoma;
RA = reactive astrocytesGelatinases in gliomas 1831
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astrocytoma), malignant gliomas (anaplastic astrocytomas or
malignant oligodendroglioma), glioblastoma, meningioma, or
other (clival chordoma or spinal ependymoma) demonstrated the
presence of gelatinase-A, -B and MT1-MMP transcripts; these
were consistently over-expressed in tumour samples compared to
normal tissues. Expression of gelatinase-A and MT1-MMP was
highly variable and did not correlate with degree of glioma
malignancy (r = 0.2024 Spearman’s rank correlation coefficient,
P = 0.2185 and r = 0.2406 Spearman’s rank correlation coefficient,
P = 0.1436 respectively) (Figure 2). In contrast, gelatinase-B RNA
levels were also variable but correlated more strongly with glioma
malignancy with higher levels seen in higher grades
(r = 0.4453 Spearman’s rank correlation coefficient, P = 0.0068).
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Figure 2 Quantification of gelatinase-A, -B, and MT1-MMP mRNA in
human brain tumours. The relative intensities of bands using densitometry
were compared to the average of two control samples, and plotted in
arbitrary units. Correlations between normal tissues and the various grades
of gliomas were determined for gelatinase-A (A), gelatinase-B (B), and MT1-
MMP (C)
116 –
92 –
67 –
N
1
N
7
N
2
N
3
N
4
N
5
N
6
Gel B
Gel A
Gel B
Gel A
Gel B
Gel A
Gel B
Gel A
116 –
92 –
67 –
116 –
92 –
67 –
116 –
92 –
67 –
G
B
M
-
2
G
B
M
G
B
M
G
B
M
G
B
M
G
B
M
G
B
M
G
B
M
L
G
G
G
B
M
G
B
M
A
A
A
O
G
B
M
A
O
G
B
M
G
B
M
A
A
G
B
M
L
G
G
C
L
N
-
1
R
A
A
A
A
A
G
B
M
-
1
G
B
M
L
G
G
Figure 3 Zymographic analysis of gelatinase-A and -B activities in human
brain tumours and normal brain. Progelatinase-A and progelatinase-B were
detected as prominent bands of activity at 72 kDa and 92 kDa respectively.
Minor, faster migrating forms that may be activated species were seen in a
few specimens. Higher molecular weight forms which may correspond to
complexes of pro-gelatinases with TIMPs were also observed
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Figure 4 Average zymographic lysis values for brain tumours and normal
brain tissue. The amount of lytic clearing (calculated as densitometric
units/microgram) from Figure 3 was quantified as described in Methods for
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Figure 5 Paraffin sections of GBMs stained using in situ hybridization for gelatinase-A (A, B, C), MT1-MMP (D, E, F), and gelatinase-B (G, H, I). Gelatinase-A:
(A) Normal cortex shows signal in neurons, less in glia, and blood vessels (100´). (B) The tumour margin of a GBM shows diffusely positive staining; signal is
seen in tumour cells and blood vessels (100´). (C) A higher power (400´) picture of the GBM seen in panel B which shows diffusely positive staining even in the
centre of the tumour. MT1-MMP: The distribution of MT1-MMP mRNA is similar to gelatinase-A. (D) Normal cortex shows MT1-MMP signal is present in
neurons and glia. (E) Both tumour cells and blood vessels show staining for MT1-MMP at lower (100´) and higher powers (400´) (F) both at the centre and
tumour margins in this GBM. Gelatinase-B: (G) Normal hippocampal cortex shows gelatinase-B is localized to neurons (the cytoplasm more than nucleus) and
glia. (H) At the tumour margin in this GBM the gelatinase-B is localized to perivascular cells (100´). There was no signal seen at the tumour centre but only at
the proliferating margins. (I) A higher magnification (400´) of panel H showing expression is restricted to cells that are not immediately adjacent to the lumens of
these small blood vessels which may be smooth muscle cells or pericytesThough few meningiomas were studied, there were very high
levels of gelatinase-A and MT1-MMP expression. Of the four
tumour specimens showing the highest levels of gelatinase-B
expression, two were from patients whose tumours subsequently
had extraneural metastases and a third from a patient whose GBM
eroded through his skull (Table 1); both are very rare events.
Zymographic analysis
The activities of gelatinase-A and -B in human brain tumours and
normal tissue were analysed by gelatin zymography. The latent
form of gelatinase-A (72 kDa) was detected in almost every tissue
extract. Low levels of both gelatinase-A and -B activity were
found in the control specimens and these were similar to the
activities seen in low grade gliomas. Progelatinase-A levels were
highly variable within each tumour type and correlated with the
degree of tumour malignancy (r = 0.4091 Spearman’s rank corre-
lation coefficient, P = 0.0061) (Figures 3 and 4). We found active
gelatinase-A only in the two patients who had extraneural metas-
tases from their GBM and in the cervical extraneural metastasis
itself in one patient. Progelatinase-A was high or intermediate in
meningiomas.
For gelatinase-B there was a trend for higher levels of activity to
be seen in more malignant gliomas; levels were highest in
GBMs, and consistently higher than activities in controls or low
grade gliomas (r = 0.3543 Spearman’s rank correlation coefficient,
P = 0.018). Gelatinase-B activity was much lower than gelatinase-
A in meningiomas (see Figure 4).
Localization of gelatinase-A, -B and MT1-MMP mRNA in
normal brain and human brain tumour tissues
The identity of cells expressing gelatinase-A, -B and MT1-MMP
was determined by in situ analysis of paraffin-embedded sections.
As observed in our analysis above, gelatinase-A and MT1-MMP
were expressed in very low, but detectable, levels in normal brain
tissue, most prominently in neurons with much less signal in glial
cells and blood vessels. In tumours, gelatinase-A and MT1-MMP
were expressed in the tumour cells and in many cell types in the
surrounding stroma, including neurons, glia and blood vessels
(Figure 5A–F). Gelatinase-B expression (Figure 5G–I) was
present at very low levels in normal tissues (principally neurons in
the hippocampus; Figure 5G and data not shown) but in the
tumours it was largely restricted to regions in blood vessels that
were undergoing endovascular proliferation at the infiltrating
border of the tumour (Figure 5H, I). For most tumours studied
there was no detectable staining of gelatinase-B in tumour cells
themselves, in the rest of the surrounding stroma, or in blood
vessels in other areas that were not proliferating, such as the centre
of the tumour. However, in three other patients the pattern of
expression was more diffuse and gelatinase-B expression was
present in all cell types in the tumour.
These in situ hybridization data can be summarized as follows:
1. Expression of gelatinase-A and MT1-MMP showed close
correspondence. Both were present in neurons in normal brain,
and in both tumour and stromal cell types in tumour. Though
in situ hybridization is not quantitative, signals were weak in
normal brain, but usually strong in tumours, indicating a
general concordance with the RT-PCR data in Figure 1.
2. Gelatinase-B was also weakly expressed in neurons in normal
brain, but in contrast to gelatinase-A and MT1-MMP its
expression in tumours was most evident in proliferating blood
vessels at tumour margins. Some tumours showed endothelial
cell positivity for gelatinase-B transcripts, while the example
shown in Figure 5 had pronounced expression in surrounding
cell types which are likely vascular smooth muscle cells or
pericytes.
DISCUSSION
The significance of the present work rests on several key points.
Firstly, this is the largest study undertaken to date on primary
human brain tumour specimens to assess the role of MMPs, and
the first to simultaneously evaluate the contributions of gelatinase-
A, gelatinase-B and MT1-MMP in a common set of brain tumour
specimens. Secondly, our results show that although all three
MMPs are likely connected in some way with malignant behaviour
in gliomas, gelatinase-B is the most closely correlated with tumour
grade. Thirdly, we provide the first in situ hybridization data to
localize the cellular origins of MMP expression in gliomas. These
studies lead to the notion that gelatinase-B is primarily involved in
tumour neovascularization, wheras the widespread and similar
localization of gelatinase-A and MT1-MMP mRNAs suggests
involvement in both invasion and angiogenesis.
Our in situ hybridization results show that the transcripts of
gelatinase-A, -B and MT1-MMP have different cellular origins.
Gelatinase-A and MT1-MMP were both expressed by many cell
types in gliomas, including the microvasculature and the tumour
cells themselves (Costello et al, 1994; Yamamoto et al, 1996;
Sawaya et al, 1996). We observed expression of both gelatinase-A
and MT1-MMP RNAs mostly in neurons in normal tissue, with
low signals from blood vessel elements. This suggests that an
important contribution of the increased expression of gelatinase-A
and MT1-MMP in malignant gliomas compared to normal brain
relates to neovascularization at tumour margins and blood vessel
expansion deep within the tumour. The other component of
increased gelatinase-A and MT1-MMP expression is the tumour
cells themselves, which confirms other immunolocalization work
(Yamamoto et al, 1996; Sawaya et al, 1996).
The restricted perivascular localization of gelatinase-B expres-
sion by in situ hybridization agrees with immunodetection of
gelatinase-B (Rao et al, 1996; Nakagawa et al, 1994). In some
tumours we observed gelatinase-B in endothelial cells and tumour
cells but in others we found expression confined to cells lying deep
to the vessel endothelium. These are most likely pericytes and/or
smooth muscle cells and angiogenesis involves cooperation
between these (Folkman, 1971; Hirschi and D’Amore, 1996).
Pericyte/vascular smooth muscle cell (VSMC) proliferation has
been suggested to be an early event in microvascular proliferation
in GBMs (Wesseling et al, 1995) where it may be critical for new
vessel formation (Wesseling et al, 1995; Haddad et al, 1992).
Gelatinase-B expression may be associated with early rapid peri-
cyte proliferation during angiogenesis and later during vessel
growth expression is taken over by endothelial cells themselves.
Several changes in gene expression in the tumour and the
surrounding vasculature must occur to induce neovascularization
(Hanahan & Folkman, 1996). Evidence that MMP activity is
required for neovascularization includes observations that TIMPs
and synthetic MMP inhibitors block angiogenesis in a number of
experimental systems (Rosenthal et al, 1994; Johnson et al, 1994;
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(Thorgeirsson et al, 1996) suggest the anti-angiogenic activities of
TIMP-1 may not be mediated by its anti-metalloproteinase effects.
Inhibition of MMP activity using a synthetic inhibitor GM6001
has also been shown to block smooth muscle cell migration in vivo
which may also contribute to the antiangiogenic actions of these
molecules (Bendeck et al, 1996). Our demonstration that gelati-
nase-B expression is localized to the vasculature at the prolifer-
ating borders in gliomas provides further support for the
importance of MMPs in angiogenesis.
We provide further support for the notion that in gliomas the
MMPs gelatinase-A and MT1-MMP are both produced and used
by the tumour cells themselves (Rao et al, 1996; Costello et al,
1994; Nakagawa et al, 1994; Yamamoto et al, 1996; Sawaya et al,
1996). While it would seem intuitively obvious that tumour cells
would produce MMPs in many systemic cancers it is the
surrounding non-tumoural stromal cells that produce them
(Heppner et al, 1996; Pyke et al, 1993; Poulsom et al, 1993). One
explanation for the differences in cellular expression of MMPs in
gliomas versus in systemic cancers may be the nature of the
specialized ‘stroma’ in the brain. Systemic cancers are often
confined by tough basement membranes and collagen-rich tissue
whereas the brain’s ECM is composed chiefly of hyaluronan and
proteoglycans (Giese and Westphal 1996). In addition to posing a
less formidable barrier to invasion the brain’s stromal environment
may regulate proteinase expression in glioma cells.
Malignant gliomas, and GBMs in particular, are both highly
invasive and vascular tumours and our results suggest that both of
these processes depend in part on the increased expression of
gelatinase-A, MT1-MMP and gelatinase-B. Changes in the
expression patterns of several MMPs might be important in
different human brain tumours at different times in their malignant
progression. For example, gelatinase-A may be expressed at an
early stage in tumorigenesis and support glioma invasion but
gelatinase-B may be employed at later stages in malignant
progression to help provide and maintain tumour vasculature. The
mechanisms underlying the upregulation of these MMPs in
gliomas are unknown and need to be better understood. This
would provide important information about the regulatory path-
ways controlling glioma invasion and angiogenesis and suggest
appropriate targets for clinical therapies.
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